CreatorsPublishersAdvertisers
View more in
Cancer

Taletrectinib May Show Promise in ROS1+ Non–Small Cell Lung Cancer

cancernetwork.com
 27 days ago

Cover picture for the articlePatients with ROS1-positive non–small cell lung cancer may derive benefit from being treated with ROS1/NTRK inhibitor taletrectinib. Taletrectinib (AB-106) demonstrated promising interim results in patients with ROS1-positive non–small cell lung cancer (NSCLC), according to data from the phase 2 TRUST trial (NCT04395677) that were presented at the 2021 Chinese Society of...

www.cancernetwork.com

Comments / 0

Comments / 0